Clinical Trials Browser

Phase 1/2 × Receptor Protein-Tyrosine Kinases × Clear all

NCT03041701 2022-04-14

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Phase 1/2 Terminated

14 enrolled 17 charts

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT00677287 2009-12-29

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer

Phase 1/2 Terminated

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00677612 2009-12-29

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer

Phase 1/2 Terminated

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00681252 2009-11-19

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer

Phase 1/2 Completed

Gastrointestinal

Stomach Neoplasms

NCT00681421 2009-11-19

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer

Phase 1/2 Completed

Gastrointestinal

Esophageal Neoplasms

NCT00681577 2009-11-19

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer

Phase 1/2 Completed

Gastrointestinal

Stomach Neoplasms

NCT00683358 2009-05-07

Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer

Phase 1/2 Unknown

Gastrointestinal

Neoplasms, Pancreatic Neoplasms